Melanotan I (afamelanotide) and melanotan II are synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH) that promote skin pigmentation through melanocortin receptor activation. Despite sharing the same therapeutic goal, they differ fundamentally in receptor selectivity, tanning mechanism, side effect profile, and regulatory status. Understanding these distinctions is essential for informed pigmentary therapy selection.
Molecular Profiles
Section titled “Molecular Profiles”Melanotan I (Afamelanotide)
Section titled “Melanotan I (Afamelanotide)”Melanotan I is a synthetic linear tridecapeptide analogue of α-MSH with enhanced melanocortin receptor selectivity:
- Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂
- Molecular weight: ~1,641 Da
- Receptor: MC1R (melanocortin 1 receptor) — highly selective
- Selectivity ratio: MC1R:MC3R:MC4R ≈ 100:10:1
- Half-life: ~2–3 hours (SC injection)
The key modification is the substitution of norleucine (Nle) for methionine at position 4, which confers resistance to oxidation and enhances MC1R binding affinity.
Melanotan II
Section titled “Melanotan II”Melanotan II is a cyclic heptapeptide analogue of α-MSH with broader receptor activity:
- Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
- Molecular weight: ~1,025 Da
- Receptor: MC1R, MC3R, MC4R (non-selective)
- Selectivity ratio: MC1R:MC3R:MC4R ≈ 1:2:3
- Half-life: ~1–2 hours (SC injection)
The cyclic structure confers metabolic stability but also broad receptor activity — a fundamental pharmacological distinction from melanotan I.
Mechanism of Tanning
Section titled “Mechanism of Tanning”MC1R-Mediated Pigmentation
Section titled “MC1R-Mediated Pigmentation”Both peptides activate melanocortin 1 receptor (MC1R) on epidermal melanocytes, triggering the melanogenesis cascade:
- MC1R activation: α-MSH or analogues bind MC1R (Gs-coupled) on melanocyte surface.
- cAMP elevation: Gs → adenylyl cyclase → cAMP accumulation.
- CREB/MITF activation: cAMP → PKA → CREB phosphorylation → MITF (microphthalmia-associated transcription factor) expression.
- Melanogenic enzyme induction: MITF upregulates tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (DCT).
- Eumelanin synthesis: Increased melanogenic activity shifts melanin production from pheomelanin (yellow-red) toward eumelanin (brown-black).
- Melanosome transfer: Mature melanosomes are transferred from melanocytes to surrounding keratinocytes, producing visible pigmentation.
Selectivity-Dependent Tanning
Section titled “Selectivity-Dependent Tanning”| Property | Melanotan I (MC1R-selective) | Melanotan II (non-selective) |
|---|---|---|
| Tanning mechanism | Direct MC1R → melanogenesis | MC1R → melanogenesis + systemic |
| Tanning quality | Even, natural | Variable, sometimes uneven |
| Tanning onset | 1–3 days | 1–2 days |
| Tanning depth | Moderate-deep | Moderate |
| Tanning durability | 2–3 weeks | 1–2 weeks |
| Photoprotection | SPF ~3–5 equivalent | SPF ~2–3 equivalent |
Melanotan I’s MC1R selectivity produces more uniform pigmentation because it acts exclusively on melanocytes. Melanotan II’s broader receptor activity produces additional systemic effects that may influence pigmentation quality.
Clinical Evidence
Section titled “Clinical Evidence”Melanotan I (Afamelanotide)
Section titled “Melanotan I (Afamelanotide)”Afamelanotide has the most robust clinical evidence:
- Erythropoietic protoporphyria (EPP): Afamelanotide (Scenesse) is FDA-approved for EPP, reducing phototoxic reactions by 60–70%. The mechanism involves melanin-mediated UV filtering rather than tanning per se.
- Solar urticaria: Open-label studies showed reduced urticaria severity with afamelanotide treatment.
- Tanning (cosmetic): Phase II trials in healthy volunteers demonstrated dose-dependent tanning (0.01–0.05 mg/kg SC) with minimal side effects. Tanning was evident within 3 days and persisted for 2–3 weeks after last dose.
- Vitiligo: Preliminary studies suggest afamelanotide combined with NB-UVB may accelerate repigmentation.
Melanotan II
Section titled “Melanotan II”Melanotan II has limited clinical trial data but extensive anecdotal evidence:
- Tanning studies: Early Phase I/II trials (1990s–2000s) demonstrated tanning at doses of 0.025–0.1 mg/kg SC, but significant side effects limited development.
- Sexual function: Melanotan II accidentally discovered to produce penile erection (via MC4R activation), leading to development of bremelanotide (PT-141) for sexual dysfunction.
- No approved indication: Melanotan II never achieved regulatory approval for any indication.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Melanotan I | Melanotan II |
|---|---|---|
| Typical tanning dose | 0.01–0.05 mg/kg | 0.025–0.1 mg/kg |
| Route | SC injection | SC injection |
| Frequency | 1–2×/week | 2–3×/week |
| Loading phase | 5–10 days | 5–10 days |
| Maintenance | 1×/week | 1–2×/week |
| Treatment duration | 2–3 months | 2–3 months |
| Discontinuation | Gradual fade over 2–3 weeks | Gradual fade over 1–2 weeks |
Both peptides require repeated dosing for cumulative tanning. A loading phase (daily dosing for 5–10 days) achieves initial pigmentation, followed by maintenance dosing to sustain tanning.
Side Effects
Section titled “Side Effects”Melanotan I
Section titled “Melanotan I”| Effect | Incidence | Severity |
|---|---|---|
| Nausea | 10–20% | Mild |
| Flushing | 5–10% | Mild |
| Injection site reactions | 15–25% | Mild |
| Fatigue | 5–10% | Mild |
| Headache | 5–10% | Mild |
| Hyperpigmentation of nevi | Common | Variable |
| Sexual arousal (females) | 5–10% | Mild |
Melanotan I’s side effect profile is generally mild and manageable. Nausea is the most common complaint, typically resolving within 30 minutes of injection. Nevi (moles) darken proportionally with surrounding skin — a cosmetic concern but not a safety signal.
Melanotan II
Section titled “Melanotan II”| Effect | Incidence | Severity |
|---|---|---|
| Nausea | 40–60% | Moderate |
| Flushing | 30–50% | Moderate |
| Appetite suppression | 20–30% | Mild |
| Penile erection (males) | 40–60% | Unwanted (cosmetic use) |
| Sexual arousal (females) | 20–30% | Variable |
| Facial flushing | 50–70% | Moderate |
| Blood pressure changes | 10–20% | Mild |
| Freckling | Common | Variable |
Melanotan II’s side effects are substantially more severe than melanotan I, driven by MC3R/MC4R activation. Penile erection in males and sexual arousal in females are particularly problematic for cosmetic tanning applications.
Safety Considerations
Section titled “Safety Considerations”| Concern | Melanotan I | Melanotan II |
|---|---|---|
| Melanoma risk | Theoretical (MC1R activation) | Theoretical (MC1R activation) |
| Nevi darkening | Common (monitor) | Common (monitor) |
| UV protection | Still required | Still required |
| FDA status | Approved (EPP) | Not approved |
| Regulatory warnings | None | EU warning (2009) |
Both peptides carry theoretical concerns about melanoma risk through MC1R activation, though no clinical evidence confirms increased risk. Both require continued UV protection despite enhanced pigmentation. The EU issued a warning against melanotan II use in 2009 due to safety concerns.
Summary
Section titled “Summary”Melanotan I and melanotan II represent two distinct pharmacological approaches to artificial tanning. Melanotan I’s MC1R selectivity produces even, natural-appearing pigmentation with a favorable side effect profile — it is the only agent to achieve regulatory approval (for EPP). Melanotan II’s non-selective melanocortin receptor activity produces tanning accompanied by significant systemic effects (nausea, flushing, sexual arousal) that limit its tolerability. For clinical applications requiring reliable photoprotection, melanotan I is the preferred choice. Melanotan II’s clinical role has been largely supplanted by its derivative bremelanotide (PT-141) for sexual dysfunction. Both agents remain investigational for cosmetic tanning, and patients should be counseled about the necessity of continued UV protection.